Peng CY - Search Results

1

Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients.

Yuan Q, Song LW, Liu CJ, Li Z, Liu PG, Huang CH, Yan Y, Ge SX, Wang YB, Peng CY, Zhang J, Kao JH, Chen DS, Chen PJ, Xia NS. Yuan Q, et al. Among authors: peng cy. Gut. 2013 Jan;62(1):182-4. doi: 10.1136/gutjnl-2012-302656. Epub 2012 Jun 14. Gut. 2013. PMID: 22698651 No abstract available.

2

Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.

Wang CC, Tseng KC, Peng CY, Hsieh TY, Lin CL, Su TH, Tseng TC, Hsu CS, Lin HH, Kao JH. Wang CC, et al. Among authors: peng cy. J Gastroenterol Hepatol. 2013 Jan;28(1):46-50. doi: 10.1111/j.1440-1746.2012.07269.x. J Gastroenterol Hepatol. 2013. PMID: 22989322

3

Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.

Yang HC, Chen CL, Shen YC, Peng CY, Liu CJ, Tseng TC, Su TH, Chuang WL, Yu ML, Dai CY, Liu CH, Chen PJ, Chen DS, Kao JH. Yang HC, et al. Among authors: peng cy. Hepatology. 2013 Mar;57(3):934-43. doi: 10.1002/hep.26121. Epub 2013 Feb 7. Hepatology. 2013. PMID: 23112104 Clinical Trial.

4

HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients.

Peng CY, Hsieh TC, Hsieh TY, Tseng KC, Lin CL, Su TH, Tseng TC, Lin HH, Wang CC, Kao JH. Peng CY, et al. J Formos Med Assoc. 2015 Apr;114(4):308-13. doi: 10.1016/j.jfma.2013.10.023. Epub 2013 Dec 5. J Formos Med Assoc. 2015. PMID: 24315616 Free article.

5

Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B.

Chien RN, Peng CY, Kao JH, Hu TH, Lin CC, Hu CT, Chen CY, Hsieh TY, Lin HC, Chuang WL; Taiwan NA-Registry Group. Chien RN, et al. Among authors: peng cy. J Gastroenterol Hepatol. 2014 Jan;29(1):185-92. doi: 10.1111/jgh.12416. J Gastroenterol Hepatol. 2014. PMID: 24354995

6

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.

Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S; HALLMARK-DUAL Study Team. Manns M, et al. Among authors: peng cy. Lancet. 2014 Nov 1;384(9954):1597-605. doi: 10.1016/S0140-6736(14)61059-X. Epub 2014 Jul 28. Lancet. 2014. PMID: 25078304 Clinical Trial.

7

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).

Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV; ESSENTIAL II Study Group. Zeuzem S, et al. Aliment Pharmacol Ther. 2015 Oct;42(7):829-44. doi: 10.1111/apt.13342. Epub 2015 Aug 4. Aliment Pharmacol Ther. 2015. PMID: 26238707 Free article. Clinical Trial.

8

Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.

Yang CC, Tsai WL, Su WW, Huang CF, Cheng PN, Lo CC, Tseng KC, Mo LR, Wang CH, Hsu SJ, Lai HC, Su CW, Liu CJ, Peng CY, Yu ML. Yang CC, et al. Among authors: peng cy. PLoS One. 2015 Sep 14;10(9):e0137852. doi: 10.1371/journal.pone.0137852. eCollection 2015. PLoS One. 2015. PMID: 26368130 Free PMC article.

9

Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan.

Wang CC, Lin CL, Hsieh TY, Tseng KC, Peng CY, Su TH, Yang SS, Hsu YC, Chen TM, Kao JH. Wang CC, et al. Among authors: peng cy. Hepatol Int. 2016 Mar;10(2):294-301. doi: 10.1007/s12072-015-9662-9. Epub 2015 Sep 23. Hepatol Int. 2016. PMID: 26399763

10

Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues.

Tseng KC, Tseng CW, Hsieh TY, Peng CY, Lin CL, Su TH, Tseng TC, Lin HH, Wang CC, Kao JH. Tseng KC, et al. Among authors: peng cy. Hepatol Res. 2016 Jun;46(7):642-9. doi: 10.1111/hepr.12600. Epub 2015 Nov 2. Hepatol Res. 2016. PMID: 26422680 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

596 results

Search Page